Belite Bio Completes NDA Submission for Stargardt Disease Drug Tinlarebant
BLTE has more than doubled off its 52-week low of $56.1.
Summary
Belite Bio announced the completion of its New Drug Application (NDA) submission to the FDA for tinlarebant, a drug for Stargardt disease type 1 (STGD1) with Breakthrough Therapy Designation, marking a significant step towards potential market approval.
Key Events · Product Development and Regulatory · BLTE
-
NDA Submission Completed
Belite Bio has completed the rolling submission of its New Drug Application (NDA) to the U.S. FDA for tinlarebant, an investigational oral therapy for Stargardt disease type 1 (STGD1).
-
Breakthrough Therapy Designation
The NDA was submitted under Breakthrough Therapy Designation (BTD), granted due to the high unmet medical need for STGD1, a rare inherited retinal disease with no currently approved treatments.
-
Next Steps for FDA Review
The completed application will undergo a 60-day review period with the FDA. If accepted, a Prescription Drug User Fee Act (PDUFA) target action date will be assigned.
-
Phase 3 Trial Success
The Phase 3 DRAGON trial demonstrated tinlarebant's ability to significantly reduce the growth rate of retinal lesions compared to placebo, supporting its potential as the first approved therapy for STGD1.
Analysis · BLTE · Life Sciences
Belite Bio has completed the New Drug Application (NDA) submission to the FDA for tinlarebant, a potential first-in-class treatment for Stargardt disease type 1 (STGD1). This is a critical regulatory milestone, following the initiation of the rolling submission in April 2026. The drug has Breakthrough Therapy Designation, highlighting the significant unmet medical need for STGD1 patients. The FDA will now begin a 60-day review period, after which a PDUFA target action date will be assigned, bringing the company closer to potential market approval and commercialization.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLTE was trading at $138.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $56.10 to $200.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.